Research progress of circulating tumor DNA in ovrian cancer

Abstract

Abstract:With the continued development of molecular biology technologies, circulating tumor DNA (ctDNA) has shown certain value in the diagnosis and treatment of malignant tumors. The emergence of next generation sequencing technology makes ctDNA detection more accurate and rapid. ctDNA plays a certain role in the early diagnosis, disease monitoring, therapeutic evaluation and medication guide of ovarian cancer by virtue of its safety and noninvasiveness. The application of ctDNA detection is insufficient at present, but with the continuous development of sequencing technology, ctDNA will play increasingly important roles in the diagnosis, personalized treatment and prognosis evaluation of ovarian cancer.

Key words:Ovarian neoplasms,Circulating tumor DNA

Yuan Qiuyue, Qiao Huimin, Zhang Shengmiao, Xia Baoguo, Bi Shuna, Chen Long. Research progress of circulating tumor DNA in ovrian cancer[J]. Journal of International Oncology, 2019, 46(1): 57-60.

References

［1］ Gold B, Cankovic M, Furtado LV, et al. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology［J］. J Mol Diagn, 2015, 17(3): 209-224. DOI: 10.1016/j.jmoldx.2015.02.001. ［2］ Giannopoulou L, KasimirBauer S, Lianidou ES. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA［J］. Clin Chem Lab Med, 2018, 56(2): 186197. DOI: 10.1515/cclm20170019. ［3］ Campan M, Moffitt M, Houshdaran S, et al. Genomescale screen for DNA methylationbased detection markers for ovarian cancer［J］. PLoS One, 2011, 6(12): e28141. DOI: 10.1371/journal.pone.0028141. ［4］ Han LY, Fan YC, Mu NN, et al. Aberrant DNA methylation of Gproteincoupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B virus associated hepatocellular carcinoma［J］. Int J Med Sci, 2014, 11(2): 164-171. DOI: 10.7150/ijms.6745. ［5］ Schrock AB, Welsh A, Chung JH, et al. Hybrid capturebased genomic profiling of circulating tumor DNA from patients with advanced nonsmall cell lung cancer［J］. J Thorac Oncol, 2018, pii: S15560864(18)332052. DOI: 10.1016/j.jtho.2018.10.008. ［6］ GarciaMurillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer［J］. Sci Transl Med, 2015, 7(302): 302ra133. DOI: 10.1126/scitranslmed.aab0021. ［7］ Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage Ⅱ colon cancer［J］. 2016, 8(346): 346ra92. DOI: 10.1126/scitranslmed.aaf6219. ［8］ Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments［J］. Curr Oncol Rep, 2015, 17(4): 15. DOI: 10.1007/s11912-015-0438-0. ［9］ Pécuchet N, Zonta E, Didelot A, et al. Baseposition error rate analysis of nextgeneration sequencing applied to circulating tumor DNA in nonsmall cell lung cancer: a prospective study［J］. PLoS Med, 2016, 13(12): e1002199. DOI: 10.1371/journal.pmed.1002199. ［10］ Hou H, Yang X, Zhang J, et al. Discovery of targetable genetic alterations in advanced nonsmall cell lung cancer using a nextgeneration sequencingbased circulating tumor DNA assay［J］. Sci Rep, 2017, 7(1): 14605. DOI: 10.1038/s41598-017-14962-0. ［11］ Ma F, Zhu W, Guan Y, et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with antiHER2 therapy［J］. Oncotarget, 2016, 7(40): 66020-66031. DOI: 10.18632/oncotarget.11791. ［12］ Giannopoulou L, KasimirBauer S, Lianidou ES. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA［J］. Clin Chem Lab Med, 2018, 56(2): 186-197. DOI: 10.1515/cclm-2017-0019. ［13］ Diamandis EP, Fiala C. Can circulating tumor DNA be used for direct and early stage cancer detection?［J］. F1000Res, 2017, 6: 2129. DOI: 10.12688/f1000research.13440.1. ［14］ Fader AN, Wang Y, Papadapoulos N, et al. Detection of tumorderived DNA with combination Pap smear and plasma testing in women with primary ovarian cancer: a potential screening test on the horizon?［J］. Gynecol Oncol, 2017, 145 Suppl 1: 24-25. DOI: 10.1016/j.ygyno.2017.03.071. ［15］ Wu Y, Zhang X, Lin L, et al. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer［J］. Asian Pac J Cancer Prev, 2014, 15(3): 11711176. ［16］ Cohen PA, Flowers N, Tong S, et al. Abnormal plasma DNA profiles in early ovarian cancer using a noninvasive prenatal testing platform: implications for cancer screening［J］. BMC Med, 2016, 14(1): 126. DOI: 10.1186/s12916-016-0667-6. ［17］ Lee HY, Lee SW, Na GH, et al. Abstract B04: early detection of ovarian cancer recurrence using p53mutated circulating tumor DNA as noninvasive biomarkers［J］. Clin Cancer Res, 2016, 22 Suppl 2: Abstract nr B04. DOI: 10.1158/1557-3265.OVCA15-B04. ［18］ Morikawa A, Hayashi T, Shimizu N, et al. PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma［J］. Oncotarget, 2018, 9(20): 15266-15274. DOI: 10.18632/oncotarget.24555. ［19］ Pereira E, CamachoVanegas O, Anand S, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers［J］. PLoS One, 2015, 10(12): e145754. DOI: 10.1371/journal.pone.0145754. ［20］ Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed highgrade serous ovarian carcinoma: a retrospective study［J］. PLoS Med, 2016, 13(12): e1002198. DOI: 10.1371/journal.pmed.1002198. ［21］ Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients［J］. Int J Cancer, 2015, 136(9): 2158-2165. DOI: 10.1002/ijc.29265. ［22］ Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer［J］. Ann Oncol, 2015, 26(8): 1715-1722. DOI: 10.1093/annonc/mdv177. ［23］ Giannopoulou L, Mastoraki S, Buderath P, et al. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with highgrade serous ovarian cancer［J］. Gynecol Oncol, 2018, 150(2): 355-360. DOI: 10.1016/j.ygyno.2018.05.026. ［24］ Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinumsensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebocontrolled, doubleblind, phase 2 trial［J］. Lancet Oncol, 2016, 17(11): 1579-1589. DOI: 10.1016/S1470-2045(16)30376-X. ［25］ Christie EL, Fereday S, Doig K, et al. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with highgrade serous ovarian cancer［J］. J Clin Oncol, 2017, 35(12): 1274-1280. DOI: 10.1200/JCO.2016.70.4627.

[1]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.
[3]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[4]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[5]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[6]	Li Chenxi, Zhao Hongwei.Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors[J]. Journal of International Oncology, 2021, 48(3): 180-183.
[7]	Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao.GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway[J]. Journal of International Oncology, 2021, 48(12): 716-722.
[8]	Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan.Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer[J]. Journal of International Oncology, 2021, 48(11): 660-665.
[9]	Yang Lifen, Song Wei, Xu Dawei, Wu Jun, Gao Ran.Mechanisms of miR-103a-3p/CHI3L1 in proliferation and vascular mimicry of ovarian cancer cells[J]. Journal of International Oncology, 2020, 47(6): 333-339.
[10]	Du Mingli, Li Guixiang, Wu Wenjuan, Zhao Lei.Application of circulating tumor DNA in targeted therapy and immunotherapy of metastatic melanoma[J]. Journal of International Oncology, 2020, 47(6): 381-384.
[11]	Xue Chen, Zhao Yue, Shi Guang, Tang Yan.Research progress of PD-1/PD-L1 inhibitors in ovarian cancer[J]. Journal of International Oncology, 2020, 47(5): 312-315.
[12]	Yang Yiting, Cheng Zhongping.The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer[J]. Journal of International Oncology, 2020, 47(4): 249-251.
[13]	Fan Yangyang, Wang Ying, Yuan Feng, Du Shanping, He Rongrong, Jia Yan.Study on the mechanism of MALAT1 targeting miR-142-3p in ovarian cancer chemotherapy resistance[J]. Journal of International Oncology, 2020, 47(2): 82-89.
[14]	Quan Ruiquan, Zhang Li, Kuang Li, Li Hongbo, Xiao Meixian.Efficacy of olaparib combined with bevacizumab in the treatment of patients with recurrent platinum-sensitive ovarian cancer and its effect on serum HE4, CA125 and CTC levels[J]. Journal of International Oncology, 2020, 47(10): 606-610.
[15]	Tang Nanmin, Yu Zhancai.Transforming growth factor-β signaling pathway and targeted therapy in ovarian cancer[J]. Journal of International Oncology, 2019, 46(9): 562-565.